|
Delaware
(State or other jurisdiction of
incorporation or organization)
11025 N. Torrey Pines Road, Suite 140
La Jolla, California
(Address of principal executive offices)
|
| |
99-0613523
(I.R.S. Employer
Identification No.)
92037
(Zip Code)
|
|
|
Title of each class to be so registered
|
| |
Name of each exchange on which each class is to be registered
|
|
|
Common stock, par value $0.0001 per share
|
| |
The Nasdaq Stock Market LLC
|
|
|
Large accelerated filer
☐
|
| |
Accelerated filer
☐
|
|
|
Non-accelerated filer
☐
|
| |
Smaller reporting company
☒
|
|
| | | |
Emerging growth company
☒
|
|
Exhibit
|
| |
Description
|
|
10.15†
|
| | | |
10.16 | | | | |
21.1 | | | | |
99.1 | | | | |
99.2 | | | Form of Notice of Internet Availability of Information Statement Materials. | |
| | | | Inhibrx Biosciences, Inc. | | | ||||||||
| | | | By: | | |
/s/ Kelly Deck
|
| | |||||
| | | | | | | Name: | | | Kelly Deck | | | | |
| | | | | | | Title: | | | Chief Financial Officer | | | | |
| Date: April 25, 2024 | | | | | | | | | | | |